DrugPatentWatch Database Preview

Drugs in Development Information for CC-223

« Back to Dashboard

What is the development status for investigational drug CC-223?

CC-223 is an investigational drug.

There have been 5 clinical trials for CC-223. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1^st 2010.

The most common disease conditions in clinical trials are Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, and Lymphoma. The leading clinical trial sponsors are Celgene Corporation and [disabled in preview].

There are thirty-three US patents protecting this investigational drug and three hundred and thirty-seven international patents.

Summary for CC-223

US Patents	33
International Patents	337
US Patent Applications	53
WIPO Patent Applications	14
Japanese Patent Applications	0
Clinical Trial Progress	Phase 1 (2010-07-01)
Vendors	31

Recent Clinical Trials for CC-223

Title	Sponsor	Phase
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma	Celgene Corporation	Phase 1
CC-223 and Ketoconazole Drug-Drug Interaction Study	Celgene Corporation	Phase 1
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects	Celgene Corporation	Phase 1

See all CC-223 clinical trials

Clinical Trial Summary for CC-223

Top disease conditions for CC-223

Top clinical trial sponsors for CC-223

See all CC-223 clinical trials

US Patents for CC-223

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
CC-223		Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3- ,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors	Signal Pharmaceuticals, LLC (San Diego, CA)
CC-223		Treatment of cancer with dihydropyrazino-pyrazines	Signal Pharmaceuticals, LLC (San Diego, CA)

International Patents for CC-223

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
CC-223	European Patent Office	3131552	2034-04-16
CC-223	Japan	2017514806	2034-04-16
CC-223	Japan	2019070012	2034-04-16
CC-223	New Zealand	629860	2034-04-16